Tumor Dormancy and Slow-Cycling Cancer Cells

Overview

Journal Adv Exp Med Biol

Specialties Biology
General Medicine

Date 2019 Oct 3

PMID 31576550

Citations 30

Authors

John E Davis Jr

Jason Kirk

Yibing Ji

Dean G Tang

Affiliations

Soon will be listed here.

Abstract

Cancer cell heterogeneity is a universal feature of human tumors and represents a significant barrier to the efficacy and duration of anticancer therapies, especially targeted therapeutics. Among the heterogeneous cancer cell populations is a subpopulation of relatively quiescent cancer cells, which are in the G0/G1 cell-cycle phase and refractory to anti-mitotic drugs that target proliferative cells. These slow-cycling cells (SCCs) preexist in untreated tumors and frequently become enriched in treatment-failed tumors, raising the possibility that these cells may mediate therapy resistance and tumor relapse. Here we review several general concepts on tumor cell heterogeneity, quiescence, and tumor dormancy. We discuss the potential relationship between SCCs and cancer stem cells (CSCs). We also present our current understanding of how SCCs and cancer dormancy might be regulated. Increasing knowledge of SCCs and tumor dormancy should lead to identification of novel molecular regulators and therapeutic targets of tumor relapse, residual diseases, and metastasis.

Citing Articles

Apoptotic cell-derived extracellular vesicles-MTA1 confer radioresistance in cervical cancer by inducing cellular dormancy.

Deng Y, Wu Q, Zhang W, Jiang H, Xu C, Chen S J Transl Med. 2025; 23(1):328.

PMID: 40087679 DOI: 10.1186/s12967-025-06350-4.

Involvement of platelet signaling pathways in colorectal cancer and new therapeutic targets.

Bonfitto P, Rodrigues B, Siqueira N, Genaro L, Rodrigues B, Oliveira P Am J Cancer Res. 2024; 14(11):5133-5153.

PMID: 39659922 PMC: 11626285. DOI: 10.62347/PJNU8987.

Drug tolerant persister cell plasticity in cancer: A revolutionary strategy for more effective anticancer therapies.

He J, Qiu Z, Fan J, Xie X, Sheng Q, Sui X Signal Transduct Target Ther. 2024; 9(1):209.

PMID: 39138145 PMC: 11322379. DOI: 10.1038/s41392-024-01891-4.

Developing a dormancy-associated ECM signature in TNBC that is linked to immunosuppressive tumor microenvironment and selective sensitivity to MAPK inhibitors.

Dong Y, Bai J, Zhou J Heliyon. 2024; 10(11):e32106.

PMID: 38868025 PMC: 11168407. DOI: 10.1016/j.heliyon.2024.e32106.

Dormant cancer cells and polyploid giant cancer cells: The roots of cancer recurrence and metastasis.

Jiao Y, Yu Y, Zheng M, Yan M, Wang J, Zhang Y Clin Transl Med. 2024; 14(2):e1567.

PMID: 38362620 PMC: 10870057. DOI: 10.1002/ctm2.1567.

References

Yadav A, Pandey P, Butti R, Radharani N, Roy S, Bhalara S . The Biology and Therapeutic Implications of Tumor Dormancy and Reactivation. Front Oncol. 2018; 8:72. PMC: 5868535. DOI: 10.3389/fonc.2018.00072. View

Ousset M, Van Keymeulen A, Bouvencourt G, Sharma N, Achouri Y, Simons B . Multipotent and unipotent progenitors contribute to prostate postnatal development. Nat Cell Biol. 2012; 14(11):1131-8. DOI: 10.1038/ncb2600. View

Salm S, Burger P, Coetzee S, Goto K, Moscatelli D, Wilson E . TGF-{beta} maintains dormancy of prostatic stem cells in the proximal region of ducts. J Cell Biol. 2005; 170(1):81-90. PMC: 2171389. DOI: 10.1083/jcb.200412015. View

Roesch A, Fukunaga-Kalabis M, Schmidt E, Zabierowski S, Brafford P, Vultur A . A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell. 2010; 141(4):583-94. PMC: 2882693. DOI: 10.1016/j.cell.2010.04.020. View

Drost J, Clevers H . Organoids in cancer research. Nat Rev Cancer. 2018; 18(7):407-418. DOI: 10.1038/s41568-018-0007-6. View

Miller M, Weissleder R . Imaging of anticancer drug action in single cells. Nat Rev Cancer. 2017; 17(7):399-414. PMC: 7552440. DOI: 10.1038/nrc.2017.41. View

Wang Y, Poulin E, Coffey R . LRIG1 is a triple threat: ERBB negative regulator, intestinal stem cell marker and tumour suppressor. Br J Cancer. 2013; 108(9):1765-70. PMC: 3658528. DOI: 10.1038/bjc.2013.138. View

Patrawala L, Calhoun T, Schneider-Broussard R, Li H, Bhatia B, Tang S . Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene. 2006; 25(12):1696-708. DOI: 10.1038/sj.onc.1209327. View

Sosa M, Bragado P, Aguirre-Ghiso J . Mechanisms of disseminated cancer cell dormancy: an awakening field. Nat Rev Cancer. 2014; 14(9):611-22. PMC: 4230700. DOI: 10.1038/nrc3793. View

10.

Chen X, Li Q, Liu X, Liu C, Liu R, Rycaj K . Defining a Population of Stem-like Human Prostate Cancer Cells That Can Generate and Propagate Castration-Resistant Prostate Cancer. Clin Cancer Res. 2016; 22(17):4505-16. PMC: 5010458. DOI: 10.1158/1078-0432.CCR-15-2956. View

11.

Choi N, Zhang B, Zhang L, Ittmann M, Xin L . Adult murine prostate basal and luminal cells are self-sustained lineages that can both serve as targets for prostate cancer initiation. Cancer Cell. 2012; 21(2):253-65. PMC: 3285423. DOI: 10.1016/j.ccr.2012.01.005. View

12.

Wilson A, Trumpp A . Bone-marrow haematopoietic-stem-cell niches. Nat Rev Immunol. 2006; 6(2):93-106. DOI: 10.1038/nri1779. View

13.

Aguirre-Ghiso J . Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer. 2007; 7(11):834-46. PMC: 2519109. DOI: 10.1038/nrc2256. View

14.

Xin L, Lukacs R, Lawson D, Cheng D, Witte O . Self-renewal and multilineage differentiation in vitro from murine prostate stem cells. Stem Cells. 2007; 25(11):2760-9. DOI: 10.1634/stemcells.2007-0355. View

15.

Wang X, Kruithof-de Julio M, Economides K, Walker D, Yu H, Halili M . A luminal epithelial stem cell that is a cell of origin for prostate cancer. Nature. 2009; 461(7263):495-500. PMC: 2800362. DOI: 10.1038/nature08361. View

16.

Roesch A, Vultur A, Bogeski I, Wang H, Zimmermann K, Speicher D . Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1B(high) cells. Cancer Cell. 2013; 23(6):811-25. PMC: 3810180. DOI: 10.1016/j.ccr.2013.05.003. View

17.

Jeter C, Badeaux M, Choy G, Chandra D, Patrawala L, Liu C . Functional evidence that the self-renewal gene NANOG regulates human tumor development. Stem Cells. 2009; 27(5):993-1005. PMC: 3327393. DOI: 10.1002/stem.29. View

18.

Lawson D, Zong Y, Memarzadeh S, Xin L, Huang J, Witte O . Basal epithelial stem cells are efficient targets for prostate cancer initiation. Proc Natl Acad Sci U S A. 2010; 107(6):2610-5. PMC: 2823887. DOI: 10.1073/pnas.0913873107. View

19.

Zhang D, Lin K, Lu Y, Rycaj K, Zhong Y, Chao H . Developing a Novel Two-Dimensional Culture System to Enrich Human Prostate Luminal Progenitors that Can Function as a Cell of Origin for Prostate Cancer. Stem Cells Transl Med. 2017; 6(3):748-760. PMC: 5442765. DOI: 10.5966/sctm.2016-0243. View

20.

Sakaue-Sawano A, Kurokawa H, Morimura T, Hanyu A, Hama H, Osawa H . Visualizing spatiotemporal dynamics of multicellular cell-cycle progression. Cell. 2008; 132(3):487-98. DOI: 10.1016/j.cell.2007.12.033. View